Showing 25–48 of 68 results

Hertab 250 mg Tablet

Molecule : LapatinibManufacturer : Hetero Healthcare

Herti 150 mg Injection

Molecule : TrastuzumabManufacturer : Hetero Healthcare

Herti 440 mg Injection

Molecule : TrastuzumabManufacturer : Hetero Healthcare

Hertraz 150 mg Injection

Molecule : TrastuzumabManufacturer : Mylan

Hertraz 440 mg Injection

Molecule : TrastuzumabManufacturer : Mylan

Ibrance 125 mg Capsule

Molecule : PalbociclibManufacturer : Pfizer

Ibyra 150 mg Tablet

Molecule : OlaparibManufacturer : Zydus

Keytruda 100 mg Vial

Molecule : PembrolizumabManufacturer : Msd

Kisqali 200 mg Tablet

Molecule : RibociclibManufacturer : Novartis

Letrafem 2.5 mg Tablet

Molecule : LetrozoleManufacturer : Adley

LuciAbe 50 mg Tablet

Molecule : AbemaciclibManufacturer : Lucius Pharma

LuciAlpe 150 mg Tablet

Molecule : AlpelisibManufacturer : Lucius Pharma

LuciCapiva 160 mg Tablet

Molecule : CapivasertibManufacturer : Lucius Pharma

LuciCapiva 200 mg Tablet

Molecule : CapivasertibManufacturer : Lucius Pharma

LuciElace 345 mg Tablet

Molecule : ElacestrantManufacturer : Lucius Pharma

LuciElace 86 mg Tablet

Molecule : ElacestrantManufacturer : Lucius Pharma

LuciNera 40 mg Tablet

Molecule : NeratinibManufacturer : Lucius Pharma

LuciOlap 150 mg Tablet

Molecule : OlaparibManufacturer : Lucius Pharma

LuciPalbo 100 mg Capsule

Molecule : PalbociclibManufacturer : Lucius Pharma

LuciPalbo 125 mg Capsule

Molecule : PalbociclibManufacturer : Lucius Pharma

LuciRibo 200 mg Tablet

Molecule : RibociclibManufacturer : Lucius Pharma

LuciTuca 150 mg Tablet

Molecule : TucatinibManufacturer : Lucius Pharma

Lumiclib 200 mg Tablet

Molecule : RibociclibManufacturer : Azista

Niranib 100 mg Capsule

Molecule : NiraparibManufacturer : Everest Pharma

Related Posts:

FDA Approves Vepdegestrant for ER+/HER2–, ESR1-Mutated Breast Cancer: A New Targeted Option

Medical Review: This article was reviewed by Dr. Sophie Reynolds on May 6, 2026. Breast cancer treatment continues to evolve

READ MORE »
First-Line Palbociclib Combination Boosts PFS in HR+/HER2+ mBC – PATINA Findings

n Medical Review: This article was reviewed by Dr. Sophie Reynolds on April 1, 2026.n n Metastatic breast cancer (mBC)

READ MORE »
Atirmociclib and Fulvestrant Together Delay Cancer Progression in HR+/HER2– Cases

Medical Review: This article was reviewed by Dr. Sophie Reynolds on March 23, 2026. Advancements in breast cancer treatment continue

READ MORE »